MDx/CDx Focus: FDA Okays PML Risk Test for Tysabri; MDxHealth Gets CLIA Nod; NY Approves AssurRx Lab
January 25, 2012
MDx/CDx Focus: FDA Okays PML Risk Test for Tysabri; MDxHealth Gets CLIA Nod; NY Approves AssurRx Lab
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- MDx/CDx Focus: FDA Accepts Pfizer's Bosutinib NDA; Kalydeco Approval; AssureRx Credit Line; and more
February 1, 2012 / Pharmacogenomics Reporter - MDxHealth and Ghent University Begin Collaboration under New Pharmacoepigenomics Center
December 12, 2012 / Pharmacogenomics Reporter - Clovis on Track to Unveil Data on New Personalized Pancreatic Cancer Treatment Option by Year End
October 10, 2012 / Pharmacogenomics Reporter - Quest Study Finds Sanger-based BRAF Mutation Test More Sensitive than Roche's Cobas Test
June 13, 2012 / Pharmacogenomics Reporter - Dx Focus: OraSure Gets FDA OK for DNA Collection Device; Quest Dengue Test Approved in Brazil
December 8, 2011 / PCR Insider